上海交通大学学报（医学版）

上海交通大学学报（医学版） ›› 2019, Vol. 39 ›› Issue (3): 316-.doi: 10.3969/j.issn.1674-8115.2019.03.017

• 论著·临床研究 • 上一篇    下一篇

预后营养指数预测转移性去势抵抗前列腺癌患者阿比特龙初始耐药和预后

方晓 1, 2，郭建功 1，黄金明 1，樊连城 2   

  1. 1. 南阳医学高等专科学校第一附属医院泌尿外科，南阳 473000；2. 上海交通大学医学院附属仁济医院泌尿科，上海 200127
  • 出版日期:2019-03-28 发布日期:2019-04-28
  • 通讯作者: 樊连城，电子信箱：787371380@qq.com。
  • 作者简介:方晓（1983—），男，主治医师，学士；电子信箱： 397199518@qq.com。

Prediction of prognostic nutritional index for the primary resistance to abiraterone and the prognosis in metastatic castration-resistant prostate cancer patients

FANG Xiao1, 2, GUO Jian-gong1, HUANG Jin-ming1, FAN Lian-cheng2   

  1. 1. Department of Urology, the First Affiliated Hospital of Nanyang Medical College, Nanyang 473000, China; 2. Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China
  • Online:2019-03-28 Published:2019-04-28

PDF (PC)

345

摘要： 目的 ·确定治疗前预后营养指数（ prognostic nutritional index，PNI）及其变化是否可以用来判断阿比特龙（ abiraterone，AA）治疗转移性去势抵抗前列腺癌（ metastatic castration-resistant prostate cancer，mCRPC）患者的初始疗效和预测患者预后。方法 ·纳入在上海交通大学医学院附属仁济医院泌尿科接受 AA治疗的 112例 mCRPC患者。在 AA治疗前及治疗 1个月后根据患者的血清白蛋白水平、外周血淋巴细胞计数，计算 PNI值 [10×血清白蛋白水平（ g/dL）+0.005×外周血淋巴细胞计数（ μL-1）]。运用单因素和多因素 Logistic回归分析确定判断 AA治疗初始疗效的预测因素。进行单因素和多因素 Cox回归分析以确定与前列腺特异性抗原（prostate-specific antigen，PSA）无进展生存期（ PSA progression-free survival，PSA-PFS）、影像学无进展生存期（ radiographic PFS， rPFS）和总生存期（ overall survival，OS）相关的预测因素。结果 ·在 112例 mCRPC患者中， 81例（72.3%）患者对 AA治疗初始有效，其中 15例患者在 AA治疗期间出现了前列腺特异性抗原的闪烁现象。多因素 Logistic回归分析结果显示，高基线 PNI值、AA治疗 1个月后 PSA水平降低和 AA治疗 1个月后 PNI值增加与对 AA初始有效显著相关。多因素 Cox回归分析结果显示，低基线 PNI值是接受 AA治疗患者 OS、rPFS和 PSA-PFS的独立预后预测因素。结论 ·独立于治疗后 PSA水平变化， AA治疗 1个月后 PNI值增加和高基线 PNI值与对 AA初始有效显著相关。此外，治疗前低基线 PNI值是 AA治疗 mCRPC患者较差预后的独立预测因素。

关键词: 转移性去势抵抗前列腺癌, 阿比特龙, 前列腺特异性抗原的闪烁现象, 初始抵抗

Abstract:

Objective · To determine whether pre-treatment prognostic nutritional index (PNI) level and its variation can predict the primary resistance to abiraterone (AA) and the prognosis in metastatic castration-resistant prostate cancer (mCRPC) patients treated with AA. Methods · A total of 112 mCRPC patients treated with AA were included in Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine. PNI levels were measured before and one month after AA treatment. PNI was calculated preoperative laboratory parameters using the formula [10×serum albumin level (g/dL) + 0.005×lymphocyte (per μL) in the peripheral blood]. Univariate and multivariate Logistic regression analyses were used to identify predictive factors of initial efficacy to AA treatment. Univariable and multivariable Cox regression analyses were performed to determine the prognostic factors that were associated with prostate-specific antigen (PSA) progression-free survival (PSA-PFS), radiographic PFS (rPFS) and overall survival (OS). Results · Eighty-one of all 112 (72.3%) patients showed initial response to AA treatment, and 15 patients experienced PSA flare during AA treatment. In multivariate Logistic regression analysis, the high baseline PNI level, the decrease of PSA level during the first month of AA treatment and the elevation of PNI level during the first month of AA treatment were significantly correlated with the initial response to AA treatment. In multivariate Cox regression analyses, the low baseline PNI level remained significant predictor of OS, rPFS and PSA-PFS. Conclusion · Independent of PSA level variation, the elevation of PNI level during the first month of AA treatment and high baseline PNI level are significantly correlated with the initial response to AA treatment. In addition, low baseline PNI level is a negative independent prognosticator of survival outcomes in mCRPC patients treated with AA.

Key words: metastatic castration-resistant prostate cancer (mCRPC), abiraterone (AA), prostate-specific antigen flare (PSA flare), primary resistance

中图分类号: